Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03643055
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
Overview
To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.
ClinicalTrials.gov
NCT03643055Drug / Compound
fluorocholine
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Phospholipid Metabolism
Ligand Class: Small Molecules
Eligibility
Inclusion
- Patients with medullary thyroid cancer (sporadic or hereditary form).
- Patients with newly diagnosed MTC for primary staging (based on fine needle aspiration cytology results).
- Patients with metastatic MTC on systemic therapy for disease activity assessment.
- Patients with suspicion of MTC recurrence for re-staging (based on biochemical, conventional imaging or clinical examination).
Exclusion
- Pregnancy.
- Patient with any PET/CT-scan exam contraindication (eg. severe claustrophobia).
Share your feedback
Help us improve your experience